ConductScience.org, home

Comparison · NCT03439345-9a602b90

Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With Referable Maculopathy (Exudates or Blot Haemorrhages Within One Disc Diameter of the Fovea)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With Referable Maculopathy (Exudates or Blot Haemorrhages Within One Disc Diameter of the Fovea). Trial comparisons, record NCT03439345-9a602b90. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03439345-9a602b90

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1860.1560.22wilson
Risk in group 20.2590.2250.296wilson
Risk difference, group 1 minus group 2-0.0734-0.121-0.0253newcombe hybrid score
Risk ratio, group 1 over group 20.7170.5750.893log
Odds ratio, group 1 over group 20.6520.4930.864log
Number needed to treat, for one fewer participant with the outcome on Fenofibrate 145 mg than on Placebo Oral Tablet13.68.2639.5from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Fenofibrate 145 mgFenofibrate 145 mg: One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)107576OG000
Group 2Placebo Oral TabletPlacebo Oral Tablet: One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)149575OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Referable Maculopathy (Exudates or Blot Haemorrhages Within One Disc Diameter of the Fovea)
Description
The presence of hard exudates or blot haemorrhages within 1 disc diameter of the macula/fovea
Time frame
4.0 years (interquartile range, 3.6 to 4.3) years
Population
Intention-to-treat comparisons among all randomised participants of the effects of allocation to fenofibrate versus placebo during the scheduled treatment period on time to the first occurrence

Source ClinicalTrials.gov

Trial

Title
Lowering Events in Non-proliferative Retinopathy in Scotland
NCT number
NCT03439345
Phases
PHASE4
Conditions
Diabetic Retinopathy
Interventions
Fenofibrate 145 mg, Placebo Oral Tablet
Lead sponsor
University of Oxford
Results first posted
2025-05-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03439345-9a602b90